EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Vergleichsstudie

Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy

Fernando C Fervenza iD, Fan Fan Hou, Chuan-Ming Hao, Gianna M Kirsztajn, Loreto Gesualdo, Tomasz Hryszko, Antonio Pisani, Dario Roccatello, Andrew S Bomback, Julie Rae, Farima Barmaki, Eriola Berisha und 5 weitere

New England Journal of Medicine · 10.09.2026 · 395 (10) · 959-971

DOI: 10.1056/nejmoa2602678 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 10.09.2026. Verfasst von Fernando C Fervenza und 16 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic, Rochester, MN. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Glomerulonephritis, Membranous, Immunosuppressive Agents, Tacrolimus. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: F. Hoffmann-La Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedGlomerulonephritis, MembranousImmunosuppressive AgentsTacrolimusAdultAgedFemaleHumansMaleMiddle AgedAdministration, OralGlomerular Filtration RateRemission InductionPatient Reported Outcome MeasuresInfectionsInfusions, IntravenousNeutropeniaTreatment OutcomeYoung Adult

Substanzen

Antibodies, Monoclonal, HumanizedImmunosuppressive AgentsobinutuzumabTacrolimus

Autor:innen und Institutionen

  • Mayo Clinic, Rochester, MN.
  • Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Huashan Hospital, Fudan University, Shanghai, China.
  • Federal University of São Paulo, São Paulo.
  • University of Bari Aldo Moro, Bari, Italy.
  • Medical University of Białystok, Białystok, Poland.

ORCID-Profile: Fernando C Fervenza

Förderung

  • F. Hoffmann-La Roche

Zitieren

APA

Fervenza, F. C., Hou, F. F., Hao, C. M., Kirsztajn, G. M., Gesualdo, L., Hryszko, T., Pisani, A., Roccatello, D., Bomback, A. S., Rae, J., Barmaki, F., Berisha, E., Schindler, T., Omachi, T. A., Garg, J. P., Malvar, A., & MAJESTY Trial Investigators (2026). Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy. New England Journal of Medicine, 395(10), 959-971. https://doi.org/10.1056/nejmoa2602678

Vancouver

Fervenza FC, Hou FF, Hao CM, Kirsztajn GM, Gesualdo L, Hryszko T, et al. Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy. New England Journal of Medicine. 2026;395(10):959-971. doi:10.1056/nejmoa2602678

BibTeX
@article{Fervenza2026,
  author = {Fervenza, Fernando C and Hou, Fan Fan and Hao, Chuan-Ming and Kirsztajn, Gianna M and Gesualdo, Loreto and Hryszko, Tomasz and Pisani, Antonio and Roccatello, Dario and Bomback, Andrew S and Rae, Julie and Barmaki, Farima and Berisha, Eriola and Schindler, Thomas and Omachi, Theodore A and Garg, Jay P and Malvar, Ana and MAJESTY Trial Investigators, MAJESTY Trial Investigators},
  title = {Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {395},
  number = {10},
  pages = {959--971},
  doi = {10.1056/nejmoa2602678}
}
Kostenlos starten →